Oculis Holding AG (OCS) | Financial Analysis & Statements
Financial Overview
Latest Annual: 2024Income Metrics
Revenue
0
Operating Income
-73.2M
Net Income
-85.8M
EPS (Diluted)
-$2.12
Balance Sheet Metrics
Total Assets
120.4M
Total Liabilities
47.0M
Shareholders Equity
73.4M
Debt to Equity
0.64
Cash Flow Metrics
Operating Cash Flow
-75.0M
Free Cash Flow
-47.7M
Revenue & Profitability Trend
Oculis Holding AG Income Statement From 2020 to 2024
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Goods Sold | - | - | - | - | - |
| Gross Profit | - | - | - | - | - |
| Operating Expenses | 73.1M | 45.8M | 32.3M | 13.2M | 12.3M |
| Operating Income | -73.2M | -45.9M | -32.4M | -13.2M | -12.3M |
| Pre-tax Income | -85.9M | -88.7M | -38.6M | -18.5M | -14.8M |
| Income Tax | -160.0K | 107.0K | 55.0K | 27.0K | 83.0K |
| Net Income | -85.8M | -88.8M | -38.7M | -18.6M | -14.9M |
| EPS (Diluted) | -$2.12 | -$2.97 | -$1.18 | -$0.57 | -$0.45 |
Income Statement Trend
Oculis Holding AG Balance Sheet From 2020 to 2024
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Assets | |||||
| Current Assets | 104.9M | 101.0M | 23.7M | 48.0M | 6.2M |
| Non-Current Assets | 15.5M | 13.3M | 13.4M | 10.1M | 10.2M |
| Total Assets | 120.4M | 114.4M | 37.1M | 58.0M | 16.4M |
| Liabilities | |||||
| Current Liabilities | 44.2M | 19.1M | 12.0M | 4.1M | 4.3M |
| Non-Current Liabilities | 2.7M | 1.5M | 123.0M | 114.9M | 55.7M |
| Total Liabilities | 47.0M | 20.6M | 135.1M | 119.0M | 60.0M |
| Equity | |||||
| Total Shareholders Equity | 73.4M | 93.7M | -98.0M | -61.0M | -43.7M |
Balance Sheet Composition
Oculis Holding AG Cash Flow Statement From 2020 to 2024
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | -85.9M | -88.7M | -38.6M | -18.5M | -14.8M |
| Operating Cash Flow | -75.0M | -47.0M | -30.6M | -12.4M | -11.9M |
| Investing Activities | |||||
| Capital Expenditures | -230.0K | -48.0K | -65.0K | -28.0K | -19.0K |
| Investing Cash Flow | -17.6M | -54.2M | -65.0K | -28.0K | -19.0K |
| Financing Activities | |||||
| Dividends Paid | - | - | - | - | - |
| Financing Cash Flow | 50.4M | 127.9M | 1.6M | 55.2M | 4.9M |
| Free Cash Flow | -47.7M | -53.9M | -28.6M | -13.9M | -12.0M |
Cash Flow Trend
Oculis Holding AG Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
63.63
Forward P/E
-8.76
Price to Book
6.28
Price to Sales
1,337.51
PEG Ratio
-8.76
Profitability Ratios
Profit Margin
0.00%
Operating Margin
-7,008.42%
Return on Equity
-85.16%
Return on Assets
-32.13%
Financial Health
Current Ratio
4.78
Debt to Equity
0.68
Beta
0.14
Per Share Data
EPS (TTM)
-$2.90
Book Value per Share
$3.12
Revenue per Share
$0.02
Peer Financial Comparison
| Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
|---|---|---|---|---|---|---|
| ocs | 1.0B | 63.63 | 6.28 | -85.16% | 0.00% | 0.68 |
| Vertex | 114.1B | 32.82 | 6.92 | -5.64% | -8.91% | 10.00 |
| Regeneron | 55.3B | 13.02 | 1.84 | 15.96% | 31.94% | 9.20 |
| Vera Therapeutics | 1.4B | -8.41 | 2.58 | -39.49% | 0.00% | 10.18 |
| Immunocore Holdings | 1.6B | -31.41 | 4.13 | -5.86% | -6.48% | 114.67 |
| Agios | 1.9B | 2.89 | 1.32 | 60.26% | 1,798.26% | 3.61 |
Financial data is updated regularly. All figures are in the company's reporting currency.